Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
25.52 USD +13.37% Intraday chart for Guardant Health, Inc. -2.74% -5.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading MT
Guardant Health's Shares Rise as Colorectal Cancer Detection Test Gets FDA Panel Recommendation MT
Sector Update: Health Care Stocks Advance Pre-Bell Friday MT
Sector Update: Health Care MT
Wall Street Rebounds From Thursday's Slide, Driving Narrow Gains for US Equity Futures Pre-Bell MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Hope for September Interest Rate Cuts MT
Top Premarket Gainers MT
Guardant Health Says Colorectal Cancer Detection Test Receives FDA Panel Recommendation MT
Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield? Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option CI
Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test DJ
U.S. FDA advisers back approval for Guardant's cancer test RE
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test MT
Guardant Health Gets EU Certification for Blood-Based Test for Comprehensive Genomic Profiling of Solid Cancers MT
Guardant Health, Inc. Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications CI
Transcript : Guardant Health, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised MT
Earnings Flash (GH) GUARDANT HEALTH Reports Q1 Revenue $168.5M, vs. Street Est of $150.1M MT
Transcript : Guardant Health, Inc., Q1 2024 Earnings Call, May 09, 2024
Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024 CI
Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating MT
Sector Update: Health Care Stocks Increase Late Afternoon MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading MT
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise MT
Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating MT
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting CI
Chart Guardant Health, Inc.
More charts
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
25.52 USD
Average target price
37.39 USD
Spread / Average Target
+46.51%
Consensus
  1. Stock Market
  2. Equities
  3. GH Stock
  4. News Guardant Health, Inc.
  5. Earnings Flash (GH) GUARDANT HEALTH Reports Q1 Revenue $168.5M, vs. Street Est of $150.1M